Literature DB >> 8328771

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.

D D Richman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8328771      PMCID： PMC187941          DOI： 10.1128/AAC.37.6.1207

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  48 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.

Authors:  D D Richman; J C Guatelli; J Grimes; A Tsiatis; T Gingeras
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

3.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity.

Authors:  M E Goldman; J H Nunberg; J A O'Brien; J C Quintero; W A Schleif; K F Freund; S L Gaul; W S Saari; J S Wai; J M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

5.  Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.

Authors:  B A Larder; K E Coates; S D Kemp
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

6.  Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.

Authors:  D L Romero; M Busso; C K Tan; F Reusser; J R Palmer; S M Poppe; P A Aristoff; K M Downey; A G So; L Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

7.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

8.  Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus.

Authors:  T R Gingeras; P Prodanovich; T Latimer; J C Guatelli; D D Richman; K J Barringer
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

9.  HIV-1 sensitivity to zidovudine and clinical outcome in children.

Authors:  G Tudor-Williams; M H St Clair; R E McKinney; M Maha; E Walter; S Santacroce; M Mintz; K O'Donnell; T Rudoll; C L Vavro
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
View more
  60 in total

Review 1.  HIV evolutionary genetics.

Authors:  A G Rodrigo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

3.  Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.

Authors:  Lingling Shen; Jianhua Shen; Xiaomin Luo; Feng Cheng; Yechun Xu; Kaixian Chen; Edward Arnold; Jianping Ding; Hualiang Jiang
Journal:  Biophys J       Date:  2003-06       Impact factor: 4.033

4.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.

Authors:  Elijah Paintsil; Ginger E Dutschman; Rong Hu; Susan P Grill; Wing Lam; Masanori Baba; Hiromichi Tanaka; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

6.  In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.

Authors:  Hao Wu; Xiao-Min Zhang; Hao-Jie Zhang; Qiwei Zhang; Zhiwei Chen; Jian-Dong Huang; Shui-Shan Lee; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01-08       Impact factor: 2.205

Review 7.  Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.

Authors:  A R Rachlis; D P Zarowny
Journal:  CMAJ       Date:  1998-02-24       Impact factor: 8.262

8.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Authors:  R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; R J Colonno; P F Lin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

9.  (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.

Authors:  R A Olmsted; D E Slade; L A Kopta; S M Poppe; T J Poel; S W Newport; K B Rank; C Biles; R A Morge; T J Dueweke; Y Yagi; D L Romero; R C Thomas; S K Sharma; W G Tarpley
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Authors:  H K Medlin; Y Q Zhu; K M Remington; T R Phillips; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.